论文部分内容阅读
目的探讨尼妥珠单抗联合放化疗治疗晚期鼻咽癌的临床疗效。方法 338例晚期鼻咽癌患者,随机分为观察组和对照组,每组169例。对照组采用单纯放化疗治疗治疗,观察组采用尼妥珠单抗联合放化疗治疗。比较两组患者的肿瘤治疗效果、预后情况以及不良反应情况。结果观察组总有效率为65.09%,明显高于对照组的41.42%,差异具有统计学意义(P<0.05);观察组疾病控制率为87.57%,明显高于对照组的50.30%,差异具有统计学意义(P<0.05)。观察组患者的无进展生存期(PFS)、总生存期(OS)和生活质量评分(QOL)均明显高于对照组,差异具有统计学意义(P<0.05)。观察组不良反应总发生率为5.92%,明显低于对照组的13.61%,差异具有统计学意义(P<0.05)。结论尼妥珠单抗联合放化疗治疗晚期鼻咽癌效果较好,可延长患者生存时间,减少不良反应,值得进一步临床研究探讨。
Objective To investigate the clinical efficacy of nimotuzumab combined with chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods 338 patients with advanced nasopharyngeal carcinoma were randomly divided into observation group and control group, with 169 cases in each group. The control group was treated with radiotherapy and chemotherapy alone. The observation group was treated with nimotuzumab combined with radiotherapy and chemotherapy. The therapeutic effect, prognosis and adverse reactions of the two groups were compared. Results The total effective rate in the observation group was 65.09%, which was significantly higher than that in the control group (41.42%), the difference was statistically significant (P <0.05). The disease control rate in the observation group was 87.57%, significantly higher than that in the control group (50.30% Statistical significance (P <0.05). The progression-free survival (PFS), overall survival (OS) and quality of life (QOL) in the observation group were significantly higher than those in the control group, with statistical significance (P <0.05). The total incidence of adverse reactions in the observation group was 5.92%, which was significantly lower than that in the control group (13.61%), the difference was statistically significant (P <0.05). Conclusion Nimotuzumab combined with radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma is better, which can prolong the survival time of patients and reduce adverse reactions, it is worth further clinical study.